Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label canakinumab for Schnitzler syndrome (SCan)
jRCT2051220139Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of canakinumab in Schnitzler syndrome, sponsored by Japan Agency for Medical Research and Development. Started Feb 2023; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on jRCT2051220139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220139.